- Article
5 Citations
3,416 Views
15 Pages
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
- Josée M. Zijlstra,
- George Follows,
- Rene-Olivier Casasnovas,
- Joost S. P. Vermaat,
- Nagesh Kalakonda,
- Sylvain Choquet,
- Brian Hill,
- Catherine Thieblemont,
- Federica Cavallo and
- Fatima De la Cruz
- + 20 authors
Selinexor, an oral selective inhibitor of nuclear export, was evaluated in the Phase 2b SADAL study in patients with diffuse large B-cell lymphoma (DLBCL) who previously received two to five prior systemic regimens. In post hoc analyses, we analyzed...